Skip to main content
NCBI home page
Frontiers in Microbiology logoLink to Frontiers in Microbiology
. 2026 Apr 2;17:1790597. doi: 10.3389/fmicb.2026.1790597

Limits of rapid diagnostics: genomic and structural insights into OXA-48–like mediated carbapenem resistance in Escherichia coli

Aya A Diab 1,†, Deena Jalal 1,†, Youssef M Fadel 2, Omar Samir 1, Lobna Shalaby 3,4, Mervat Elanany 5,6, Sabah A Abo-Elmaaty 7, Ramy K Aziz 1,8, Ahmed AbdelAziz Sayed 1,9,*, Mervat G Hassan 7
PMCID: PMC13085321  PMID: 42005841

Abstract

Carbapenem-resistant Escherichia coli (CREC) represent a major clinical threat because of limited treatment options and frequent multidrug resistance. While rapid molecular diagnostics improve treatment outcomes, the detection of carbapenemase genes, such as blaOXA-48-like, does not always correspond to phenotypic resistance, complicating management of bloodstream infections. We investigated 20 bloodstream E. coli isolates, from pediatric cancer patients at Children’s Cancer Hospital Egypt 57357, that harbored blaOXA-48-like genes yet were phenotypically susceptible to meropenem. Whole-genome sequencing was performed to characterize resistomes, virulomes, plasmid content, and the genetic context of OXA-48–like variants. The isolates belonged to 12 sequence types (STs), with ST405 and ST410 being the most frequent. blaOXA-244 predominated and was primarily chromosomal, whereas blaOXA-181 and blaOXA-484 were plasmid-borne, often co-localized with qnrS1. Resistome and virulome profiles were broadly conserved across meropenem-susceptible and resistant isolates. Structural modeling and protein–ligand interaction analyses of OXA-48, OXA-244, OXA-181, and OXA-484 illustrate how the substitutions Arg214Gly and Thr104Ala are consistent with localized alterations in active site geometry, despite preservation of key ligand interactions. These observations help explain the observed discordance between genotype and phenotype and highlight the limitations of relying solely on rapid gene detection for treatment decisions. Collectively, these findings highlight the need to interpret rapid PCR-based carbapenemase detection in conjunction with phenotypic susceptibility testing and genomic context, supporting balanced antimicrobial decision-making that preserves carbapenem use when appropriate while maintaining vigilance against the silent spread of carbapenemase-producing strains.

Keywords: bioinformatics, carbapenem resistance, genomics, OXA-48 variants, protein structural modeling

Graphical abstract

Three-panel flowchart illustration describing workflow for E. coli analysis: Panel one shows human sampling, gene testing, and meropenem sensitivity testing; panel two depicts culturing, DNA extraction, sequencing; panel three presents bioinformatics including whole genome sequencing analysis, quality control, phylogenetic mapping, resistance profiling, virulence factors identification, and structural protein modeling.

Open in a new tab

A three-step workflow: (1) Sample collection involves isolating E. coli (n = 20), and testing for OXA-48–like genes using Carba-R Gene Xpert and antimicrobial resistance using VITEK® 2. (2) Sample processing includes bacterial subculture, DNA extraction, library preparation, and sequencing using Illumina® MiSeq DX. (3) Bioinformatics analysis is subdivided into (i) WGS analysis, which encompasses quality control, genome mapping, antimicrobial resistance profiling, and virulence factor; and (ii) protein structural analysis, which encompasses structure prediction and binding energy assays.

Introduction

Carbapenems are a class of beta-lactam antibiotics characterized by a beta-lactam ring fused to an unsaturated five-membered ring in which a carbon atom replaces sulfur. This unique structure provides the carbapenems with enhanced stability and resistance to most beta-lactamases, including extended spectrum beta-lactamases (ESBLs; Elshamy and Aboshanab, 2020). Carbapenems gained their prominence from their broad-spectrum activity against both Gram-positive and Gram-negative bacteria, including some multidrug-resistant bacteria, such as Escherichia coli (Papp-Wallace et al., 2011; El-Gamal et al., 2017; Bassetti et al., 2009). Currently, the carbapenems available in the pharmaceutical market are meropenem, imipenem, ertapenem, and doripenem. Because of its combined broad-spectrum activity, favorable safety profile, and short half-life that allows flexible dosing schedules, meropenem is considered the preferred carbapenem treatment option (Elshamy and Aboshanab, 2020; Shien Lo et al., 2012; Tamma et al., 2022). The most common mechanisms of carbapenem resistance in Enterobacterales is the expression of carbapenemase enzymes, whose encoding genes can be transferred among members of the Enterobacterales through mobile genetic elements (Tilahun et al., 2021). The most frequently identified genes encoding carbapenemases are class A KPC, class B metallo-β-lactamases (IMP, VIM and NDM) and class D OXA-type enzymes (OXA-48-like) (Dagher et al., 2018). In addition, carbapenem resistance can arise from the combined presence of AmpC enzymes or ESBLs with reduced outer membrane permeability, most commonly mediated by mutations or loss of outer membrane porins (Hamzaoui et al., 2018; Larkin et al., 2020; Wong et al., 2019).

Traditionally, the treatment of carbapenem-resistant Enterobacterales bloodstream infections (CRE-BSIs) relied primarily on time-consuming phenotypic antimicrobial susceptibility testing and carbapenem minimum inhibitory concentrations (MICs). High-dose or prolonged-infusion carbapenems for isolates with lower MICs, often combined with a second active agent such as an aminoglycoside or polymyxin (Madney et al., 2025). The introduction of rapid molecular diagnostics, such as PCR-based detection, represented a major advance in CRE-BSI management by enabling early detection of carbapenemase genes directly from blood cultures (Ziad et al., 2025). Identification of specific carbapenemases, such as KPC, NDM, or OXA-48-like enzymes, increasingly informed early therapeutic escalation to targeted β-lactam/β-lactamase inhibitor combinations, including ceftazidime–avibactam, often before complete phenotypic susceptibility data became available. This approach has been associated with improved timeliness of appropriate therapy and better clinical outcomes in multiple studies (Banerjee and Humphries, 2017; Satlin et al., 2022; Jankowski, 2021). However, the clinical utility of rapid gene-based diagnostics depends on the assumption that detection of a carbapenemase gene reliably predicts functional resistance.

Although ceftazidime–avibactam is a generally effective and well tolerated treatment, unnecessary use can exert selective pressure that drives rapid resistance, including blaKPC mutations and acquisition of metallo-β-lactamases such as NDM, which are not inhibited by avibactam (Perez et al., 2016; Liu et al., 2025). Exposure in high-burden hospital environments or immunocompromised patients has been linked to plasmid-mediated resistance evolution (Jalal et al., 2025). Consequently, premature escalation to ceftazidime–avibactam when carbapenems remain active may inadvertently promote the emergence and dissemination of more difficult-to-overcome resistance mechanisms.

Carbapenem-resistant E. coli (CREC) have emerged as a major global health threat owing to resistance to last-line carbapenems and frequent multidrug co-resistance (Luo et al., 2018; Huang et al., 2024). In 2017, the World Health Organization classified CREC among the highest-priority pathogens requiring urgent development of new therapeutic options (Huang et al., 2024). In addition to antimicrobial resistance, CREC often possess virulence-associated factors that facilitate bloodstream invasion, contributing to severe infections such as bacteremia and septicemia, and resulting in increased morbidity, mortality, and healthcare burden (Dagher et al., 2018; Huang et al., 2024; Slown et al., 2022; Jomehzadeh et al., 2022).

At the Children’s Cancer Hospital Egypt 57357 (CCHE 57357), the implementation of rapid diagnostics has significantly accelerated treatment initiation and improved patient care (Madney et al., 2025). However, a clinical challenge has emerged regarding the correlation between molecular and phenotypic resistance profiles in some isolates. Our surveillance of carbapenem-resistant Enterobacterales (CRE) isolates revealed that approximately 27% (n = 53/189) harbored blaOXA-48 as the sole carbapenemase gene (Jalal et al., 2025). Nearly half of these isolates demonstrated preserved phenotypic susceptibility to meropenem despite being resistant to ertapenem. Under current rapid-diagnostic protocols, patients infected with these bacteria are often escalated to ceftazidime–avibactam–based therapy based on gene detection alone, despite the retained phenotypic activity of meropenem.

In this study, we applied whole-genome sequencing to systematically and comprehensively investigate the molecular basis of discordance between rapid molecular detection of carbapenemase genes and preserved phenotypic susceptibility to meropenem in a subset of carbapenemase-producing E. coli bloodstream isolates. Specifically, we sought to determine whether genetic variation within OXA-48-like enzymes and associated genomic features could explain the observed susceptibility patterns and contribute to bloodstream infection potential. By integrating phenotypic data with genomic and protein structural analyses, we aimed to clarify the limitations of gene-based diagnostics in guiding antimicrobial therapy and inform more precise treatment strategies for CRE bloodstream infections.

Materials and methods

Ethical approval

The Institutional Review Board at CCHE 57357 approved the study following ICH GCP guidelines and local and institutional regulations.

Sample collection and antimicrobial susceptibility testing

From the initial cohort of 189 CRE isolates, we focused on a specific subset of 20 E. coli isolates that tested positive for blaOXA-48 via the Cepheid Xpert Carba-R assay but demonstrated phenotypic susceptibility (or intermediate susceptibility) to meropenem by disc diffusion to clarify the molecular mechanisms underlying this discrepancy. Antimicrobial susceptibility testing (AST) was carried out using the Vitek 2 AST cards GN222 (bioMérieux SA, Marcy l’Etoile, France) following the manufacturer’s protocols. Results interpretation was conducted in accordance with the guidelines established by the Clinical and Laboratory Standards Institute (CLSI; Clinical and Laboratory Standards Institute (CLSI), 2023). Based on CLSI breakpoints, isolates with MICs of ≤1 μg/mL were considered sensitive, those with MICs of 2 μg/mL were intermediate, and isolates with MICs ≥4 μg/mL were classified as resistant, providing clear criteria for susceptibility interpretation.

DNA extraction and whole genome sequencing

For each sample, a single colony was inoculated in 2 mL Luria-Bertani (LB) medium then incubated overnight at 37 °C in a shaking incubator. The samples were centrifuged at 14,000 × g for 10 min to pellet the bacterial cells. DNA was then extracted using the PureLink™ Microbiome DNA Purification Kit following the manufacturer’s instructions (Thermo Fisher Scientific, United States). The library preparation was performed using Nextera® XT DNA Library Preparation Kit and Nextera® XT Index Kit by Illumina according to the manufacturer’s instructions (Illumina, United States). The libraries were then normalized, pooled and subjected to 300-base paired-end read sequencing using an Illumina MiSeqDx system according to the manufacturer’s protocol (Jalal et al., 2021).

Bioinformatics analysis

The bioinformatics pipeline (Figure 1) was previously described (Jalal et al., 2025) and is summarized in Supplementary Figure 1. Below is a brief summary of the pipeline.

Figure 1.

Flowchart diagram describing two pipelines: Whole Genome Sequencing analysis on the left, detailing steps from raw FASTQ processing, assembly, plasmid reconstruction, and annotation using various bioinformatics tools; and Protein Structural Analysis on the right, mapping from FASTA sequence prediction with AlphaFold to structure alignment, ligand docking, and structural or ligand interaction assessment using PyMOL and PLIP.

Open in a new tab

Flowchart illustrates the bioinformatics pipeline used to analyse whole genome sequencing data, including preprocessing (Fastp), assembly (Unicycler, bwa-mem), and annotation (Abricate, AMRFinderPlus) to identify MLST, plasmids, virulence, and AMR genes.

a. Whole-genome sequencing (WGS) assembly and multiple locus sequence typing (MLST)

Read pairs were quality filtered, and adapter sequences were removed by fastp (Chen et al., 2018). Unicycler (Wick et al., 2017) was used to de novo assemble the merged read. Sequence types were determined by database (https://pubmlst.org/; accessed on January 1, 2023; Jolley and Maiden, 2010) following the Achtmann scheme for E. coli.

b. Identification of resistome, virulome, and mobile genetic elements

plsMD (Lotfi et al., 2025) was used for reconstructing full-length plasmid sequences and extracting them from the remaining chromosomal contigs. Both were analyzed to identify AMR genes against the AMRfinderPlus database (Feldgarden et al., 2021), virulence factor (VF) genes with VFDB (Chen et al., 2005), insertion sequences (ISs) with ISfinder (Siguier et al., 2006), plasmid replicons using Plasmidfinder tool (Carattoli et al., 2014), and relaxase types using MOB-typer (Robertson and Nash, 2018).

c. Protein structural analysis

The PDB structures 6P97, 6P98, and 6P99 were retrieved from the RCSB Protein Data Bank (Smith et al., 2019), and their co-crystallized ligands (imipenem, meropenem, and ertapenem, respectively) were isolated using PyMOL1 and saved as separate files. The 6p98, 6p97, and 6p99 PDB structures were retrieved from the RCSB PDB database. AlphaFold (Jumper et al., 2021) was used to computationally generate the protein structures of OXA-48, OXA-181, OXA-244, and OXA-484. To study ligand interactions, the AlphaFold-generated OXA-48 structure was aligned to the experimental structures (6P97–6P99) in PyMOL, and the corresponding ligands were subsequently transferred to the aligned model and saved as protein–ligand complexes. Protein–ligand interactions were analyzed by the PLIP web service (Adasme et al., 2021). Structural comparisons between the different protein variants were performed with the PyMOL Molecular Graphics System, Version 2.5.2 (Schrödinger, LLC) for visualization and analysis.

Results

OXA-48-like variants across several STs in Escherichia coli

Using the Oxford scheme, we categorized all 20 isolates into 12 distinct STs. The predominant ST was ST405 (four samples), followed by ST410 (three samples), and then ST10, ST131, and ST361 (two samples each). Each of the remaining isolates belonged to a different type (ST1139, ST155, ST167, ST3268, ST4981, ST501 and ST69).

Phenotypic susceptibility despite carbapenemase presence

Upon examining the presence of blaOXA-48 in the isolates, we observed that all 20 genomes harbored blaOXA-48-like genes, including blaOXA-244, blaOXA-181, and blaOXA-484, which were associated with varying resistance profiles. blaOXA-244 was the most frequently detected variant, present in the majority of samples (n = 15), while blaOXA-181 was identified in four isolates (A01, A06, A15, and A17). A single isolate (A08) carried blaOXA-484 (Table 1 and Supplementary Figure 1).

Table 1.

Distribution and genomic location of OXA carbapenemase variants among study isolates.

Isolate MLST blaOXA-48-like variant Genomic location Genetic context Assembly size and depth Reconstructed plasmid size and number of contigs Meropenem MIC (mg/L)—interpretation Mobility features Replicon type
A01 405 bla OXA-181 Plasmid 12,503 bp; 3.79x 69,261 bp (43 contigs) 1–S MOBF relaxase, MPF_F, conjugative rep_cluster_1195/IncFIC(FII)/ColKP3
A02 501 bla OXA-244 Chromosome IS10A–IS4 1,774 bp; 2.47x – ≤0.5–S
A03 1,139 bla OXA-244 Chromosome IS10A–IS4 1,769 bp; 3.05x – 1–S
A04 410 bla OXA-244 Chromosome IS10A–IS4 1,774 bp; 2.15x – ≤0.5–S
A05 69 bla OXA-244 Chromosome – 2,233 bp; 1.48x – 1–S
A06 405 bla OXA-181 Plasmid 8,568 bp; 3.69x 70,196 bp (42 contigs) ≤0.5–S MOBF relaxase, MPF_F, conjugative rep_cluster_1195/IncFIC(FII)/ColKP3
A07 10 bla OXA-244 Chromosome IS10A–IS4 1,774 bp; 3.41x – ≤0.5–S
A08 10 bla OXA-484 Plasmid 12,563 bp; 1.88x 51,366 bp (5 contigs) ≤0.5–S MOBP relaxase, MPF_T, conjugative rep_cluster_1195/IncX3/ColKP3
A09 405 bla OXA-244 Chromosome – 2,231 bp; 2.48x – 1–S
A10 361 bla OXA-244 Chromosome IS10A–IS4 1,767 bp; 1.23x – 1–S
A11 – bla OXA-244 Chromosome IS10A–IS4 1,774 bp; 1.82x – 2–I
A12 361 bla OXA-244 Chromosome IS10A–IS4 1,767 bp; 3.95x – –S
A13 131 bla OXA-244 Chromosome IS10A–IS4 1,773 bp; 1.67x – ≤0.25–S
A14 131 bla OXA-244 Chromosome IS10A–IS4 1,774 bp; 0.49x – 1–S
A15 405 bla OXA-181 Plasmid 8,568 bp; 3.65x 70,969 bp (16 contigs) 1–S MOBF relaxase, MPF_F, conjugative rep_cluster_1195/IncFIC(FII)/ColKP3
A16 4,981 bla OXA-244 Chromosome IS10A–IS4 1,772 bp; 1.40x – ≤0.5–S
A17 155 bla OXA-181 Plasmid 8,567 bp; 3.23x 71,144 bp (62 contigs) ≤0.5–S MOBF relaxase, MPF_F, conjugative rep_cluster_1195/IncFIC(FII)/ColKP3
A18 167 bla OXA-244 Chromosome IS10A–IS4 1,767 bp; 3.74x – 1–S
A19 3,268 bla OXA-244 Chromosome – 2,231 bp; 1.30x – ≤0.5–S
A20 131 bla OXA-244 Chromosome IS10A–IS4 1,785 bp; 2.91x – ≤0.5–S
Open in a new tab

To contextualize these findings, we compared the carbapenemase gene content of the meropenem-susceptible isolates with that of meropenem-resistant isolates (n = 169) collected during the same surveillance period from the same hospital as part of a previously characterized CRE bloodstream infection cohort (Jalal et al., 2025). Notably, none of the meropenem-susceptible isolates carried other carbapenemase genes conferring high-level resistance to carbapenems, such as blaNDM, which were restricted to meropenem-resistant strains in the larger cohort (Supplementary Figure 1 and Jalal et al., 2025).

Similar resistomes and virulomes across meropenem-susceptible and resistant isolates

The majority of resistance determinants identified in the previously characterized CRE cohort, including β-lactamase genes (blaEC, blaTEM-1, blaCTX-M-15), quinolone resistance mechanisms mediated by gyrA/parC mutations and qnrS1, aminoglycoside-modifying enzymes, sulfonamide resistance genes (sul1/sul2), macrolide resistance genes, and multidrug efflux systems, were also detected in the meropenem-susceptible isolates in this study, indicating a shared resistome background (Supplementary Figure 1 and Jalal et al., 2025).

Similarly, virulence profiling revealed no major qualitative differences between the meropenem-susceptible and meropenem-resistant isolates. Core virulence gene clusters involved in adhesion, biofilm formation, iron acquisition, and interbacterial competition, including fim, csg, ent, yag/ecp, ybt, and type VI secretion system components, were conserved across both phenotypes, consistent with comparable invasive potential in bloodstream infections (Supplementary Figure 2 and Jalal et al., 2025).

Collectively, these data indicate that phenotypic meropenem resistance in this population is primarily driven by the acquisition of highly active carbapenemases rather than broad differences in AMR gene content or virulence gene repertoires, supporting the presence of shared resistomes and virulomes between meropenem-susceptible and -resistant lineages.

OXA-48–like genes are predominantly chromosomal across Escherichia coli sequence types

To determine the genomic context of the blaOXA-48-like genes, we used plsMD, which separates plasmid-derived sequences from chromosomal contigs and reconstructs complete plasmid sequences that are otherwise difficult to resolve from short-read assemblies. Despite the overall similarity in AMR gene content, the different blaOXA-48-like variants exhibited distinct genetic contexts. blaOXA-244 was found predominantly integrated into the chromosome across multiple E. coli STs, including major STs such as ST410, ST405, ST361, and ST131, with lower prevalence in ST167. Because short-read assemblies frequently break at repetitive regions, such as insertion sequences and transposable elements, we examined the contigs harboring blaOXA-244 to infer associated mobilizable elements. In most isolates, blaOXA-244 was associated with a single upstream IS10A element without a corresponding downstream insertion sequence, and a few isolates lacked any insertion sequences entirely. This configuration suggests a remnant transposition event followed by chromosomal stabilization, consistent with limited ongoing mobility of blaOXA-244. Genetic maps of the contigs harboring blaOXA-244 are presented in Figures 2a,b.

Figure 2.

Panel a displays a linear DNA map with blaOXA-244 (yellow arrow) adjacent to IS4 family and dmlR (purple arrow) genes; panel b shows blaOXA-244 and dmlR separated on the same linear scale. Panel c contains a circular map of the IncX3/ColKP blaOXA-484 plasmid showing various gene arrows and labeled insertion sequences. Panel d presents a circular map of the IncFIC(FII)/ColKP3 blaOXA-181 plasmid, highlighting gene annotations and insertion sequences in similar style.

Open in a new tab

Genomic context of blaOXA-48-like variants in E. coli. SnapGene software (URL: https://www.snapgene.com) was used to visualize the genetic environments of blaOXA-48-like genes. (a,b) Chromosomal blaOXA-244 in multiple STs, typically flanked by a single upstream IS10A element. (c) Plasmid-borne blaOXA-181 on IncFIC(FII)/ColKP3 plasmids with qnrS1. (d) Plasmid-borne blaOXA-484 on IncX3/ColKP3 plasmids with qnrS1. Arrows indicate gene orientation: yellow, AMR genes; blue, replicon types; purple, other genes; grey, insertion sequences.

In contrast, blaOXA-181 and blaOXA-484 was plasmid-borne as identified by the reconstructed plasmids using plsMD (Figures 2c,d). blaOXA-181 was found residing on IncFIC(FII)/ColKP3 replicon-type plasmids and co-harbored with the quinolone resistance gene qnrS1 (Figure 2c). Similarly, blaOXA-484 was identified on IncX3/ColKP3 replicon-type plasmids, also in association with qnrS1 (Figure 2d). This consistent co-localization suggests co-transfer of carbapenemase and quinolone resistance determinants, suggesting quinolone exposure as a potential selective driver for the dissemination and maintenance of low-level carbapenem resistance in E. coli. Details of the genetic environment surrounding blaOXA-48-like genes, including gene location, assembly contig length and depth, reconstructed plasmid length and number of contigs, and replicon/relaxase types, are summarized in Table 1.

Active site conformational differences among OXA-48-like variants

To examine structural features that may contribute to the observed phenotypic susceptibility profiles, we performed comparative structural modeling of OXA-48 and its variants (OXA-181, OXA-244, and OXA-484) in complex with meropenem, imipenem, and ertapenem. As crystallographic structures are available only for OXA-48, AlphaFold was used to model all variants, including OXA-48 itself, to ensure methodological consistency and minimize modeling-related bias. To validate the modeled structures, we analyzed ligand interactions of OXA-48 with meropenem, imipenem, and ertapenem (Supplementary Figure 1) using ligands extracted from published crystal structures (PDB IDs: 6P98, 6P97, and 6P99, respectively). The predicted interactions were highly concordant with crystallographic data, involving conserved residues such as Ser70, Ser118, Val120, Leu158, Lys208, Tyr211, and Arg250. Additional hydrophobic contacts involving Leu247 and Gly248 were observed for ertapenem, consistent with its distinct side-chain chemistry.

Overlay of the backbone structures of OXA-48 and its variants revealed no global conformational differences (Figure 3a). However, localized structural changes were evident in the active site region. In OXA-244 and OXA-484, the Arg214Gly substitution resulted in widening of the active site groove between residues 214 and 124, increasing the distance from approximately 4.5 Å in OXA-48 to 10.5 Å (Figures 3b,c). In addition, OXA-181 and OXA-484 harbor a Thr104Ala substitution, which introduced a subtle structural rearrangement adjacent to the active site (Figures 3d,e). While these substitutions did not markedly alter direct ligand–residue contacts in our models, they modified the geometry of the active site and its surrounding region. These structural differences are consistent with previously reported biochemical studies demonstrating reduced catalytic efficiency of OXA-244 and OXA-484 relative to OXA-48 and OXA-181, particularly against meropenem and ertapenem, as well as substrate-dependent effects on imipenem hydrolysis (Rima et al., 2021; Gonzalez et al., 2024). Together, these observations indicate that localized active site architecture, rather than gross structural rearrangements, is associated with the phenotypic susceptibility patterns observed in isolates carrying OXA-48–like variants (Smith et al., 2019; Docquier et al., 2009).

Figure 3.

Panel a presents an overlayed ribbon diagram of protein structures highlighting structural similarities and differences, with proteins shown in green, yellow, and magenta. Panels b and c display surface electrostatic representations of OXA-48 and OXA-244 proteins, featuring colored areas and ligand binding in stick models. Panels d and e further compare surface renderings of OXA-48 and OXA-181 proteins with similar ligand representations.

Open in a new tab

Changes in active site architecture underlie the reduced carbapenemase activity in OXA-48 variants. (a) Overlay of OXA-48, OXA-181, OXA-244, and OXA-484 backbone structures, demonstrating identical overall conformations. (b,c) Surface structures of OXA-48 and OXA-244 with meropenem bound in the active site. Active site Ser70 is highlighted in green, Gln124 in magenta, and residue 214 is shown in orange (arginine in OXA-48 and glycine in OXA-244). (d,e) Surface structures of OXA-48 and OXA-181 with meropenem bound in the active site. Residue 104 is highlighted in yellow (threonine in OXA-48 and alanine in OXA-181).

Discussion

The global spread of CREC represents a critical public health threat because of their high burden of resistance, limited treatment options, and potential for widespread transmission (Huang et al., 2024). Their dissemination, facilitated by interactions across human, animal, and environmental reservoirs, poses severe challenges for clinical control. Early detection of carbapenem resistance is essential for appropriate treatment, particularly in vulnerable patients. Rapid PCR-based diagnostics have become an integral part of routine care, facilitating faster treatment initiation and improved outcomes; however, contradictory results between phenotypic and PCR-based methods complicate interpretation and management.

In this study, we provide mechanistic insight into one major contributor to genotype–phenotype discordance by identifying specific OXA-48-like variants, OXA-244, OXA-181, and OXA-484, which exhibit attenuated meropenem-hydrolyzing activity. Notably, blaOXA-244 was the most prevalent variant in our cohort and was found integrated into the chromosome across multiple STs. This chromosomal localization within transposable elements has been reported in several organisms (Pedraza et al., 2022) and suggests a shift toward stable inheritance. This variant arises from a single-point mutation in the blaOXA-48 gene, resulting in an Arg214Gly substitution in OXA-244 (Rima et al., 2021; Hoyos-mallecot et al., 2017; Masseron et al., 2020). While blaOXA-181 is traditionally associated with IncX3 plasmids through specific insertion sequences (Qin et al., 2018; Pitout et al., 2020), we found it associated with IncFIC(FII)/ColKP3 replicon type plasmids in our isolates, highlighting regional genomic diversity. In contrast, the blaOXA-484 variant, which is closely related to blaOXA-181 but carries the Arg214Gly substitution in OXA-484, remained exclusively associated with IncX3 plasmids (Gonzalez et al., 2024; Findlay et al., 2017; Ramsamy et al., 2022; Hooban et al., 2022; Findlay et al., 2023; Ge et al., 2023; Yu et al., 2022). The inferred genomic locations and surrounding mobile elements are based on plasmid reconstructions generated by plsMD, and therefore depend on the accuracy of short-read–based plasmid assembly. Although plsMD demonstrates strong performance in reconstructing plasmid sequences (Lotfi et al., 2025), long-read sequencing would be required to fully resolve plasmid structures and confirm the precise genetic contexts.

To align our observations with established structural data, we performed a structural comparison of OXA-48 and its variants to assess whether variant-specific substitutions were associated with localized changes in active site architecture. Although the overall backbone structures remain highly conserved, our modeling highlights variant-specific alterations in the active site region. Specifically, the Arg214Gly substitution in OXA-244 and OXA-484 substantially widens the active site groove, consistent with the established role of the β5–β6 loop and Arg214 in substrate recognition (Smith et al., 2019; Docquier et al., 2009; Oueslati et al., 2020). This principle is further supported by the loop-deficient OXA-163 variant, which has been shown to exhibit impaired catalytic activity (Stojanoski et al., 2021). In addition, the Thr104Ala substitution present in OXA-181 and OXA-484 introduces a more subtle conformational change adjacent to the active site, which may influence substrate accommodation (Docquier et al., 2009). Although this study is limited by reliance on in silico modeling, where functional effects can be influenced by gene expression, plasmid copy number, or other cellular factors, and by a relatively small number of isolates, our observations align with previously published biochemical studies (Gonzalez et al., 2024; Oueslati et al., 2020; Hirvonen et al., 2021). Specifically, those studies report reduced and substrate-dependent catalytic efficiencies for OXA-244 and OXA-484 relative to OXA-48 and OXA-181, (kcat/Km for meropenem: OXA-48 6 mM−1·s−1, OXA-181 1.5 mM−1·s−1, OXA-484 0.2 mM−1·s−1, OXA-244 0.8 mM−1·s−1) supporting the biological relevance of the structural changes we observed (Gonzalez et al., 2024; Oueslati et al., 2020; Hirvonen et al., 2021).

While these results may seem to favor phenotypic assays over rapid PCR, the detection of attenuated variants remains a vital clinical issue. Relying solely on meropenem susceptibility could allow the silent spread of these variants, a risk that has also been reported in other carbapenem-resistant organisms (Pedraza et al., 2022). Although these isolates demonstrate in vitro susceptibility, they may exhibit clinical resistance due to the high inoculum often seen in bloodstream infections. Additionally, the presence of these genes represents a “pre-resistant” state, where minor secondary mutations, such as porin loss, can rapidly enhance resistance under selective pressure. Consequently, the clinical decision to escalate to ceftazidime-avibactam in these cases serves as an appropriate risk-mitigation strategy to ensure bactericidal activity in immunocompromised patients. In this context, rapid molecular diagnostics may aid early detection; alternatively, reduced susceptibility to ertapenem may provide an additional phenotypic indicator of OXA-48-like carbapenemases, as these enzymes often hydrolyze ertapenem more efficiently than other carbapenems. Altogether, this study addresses the commonly observed paradox of genotype–phenotype discordance in detecting carbapenemase-mediated resistance and emphasizes the need for diagnostic assays capable of distinguishing between high-activity and attenuated OXA-48-like variants to support precise treatment decisions.

Funding Statement

The author(s) declared that financial support was received for this work and/or its publication. This study is partially funded by Pfizer Global Medical grant #54699605. The funder was not involved in the study design, data collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.

Edited by: Taru Singh, Amity University, India

Reviewed by: Angeliki Mavroidi, General University Hospital of Patras, Greece

Alexander Tristancho, Hospital Universitario Miguel Servet, Spain

Data availability statement

All data generated and analyzed during this study are included in this article and published online on NCBI with the SRA accession number PRJNA1209707.

Ethics statement

Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used.

Author contributions

AD: Writing – original draft, Methodology, Investigation. DJ: Visualization, Formal analysis, Investigation, Methodology, Writing – original draft. YF: Visualization, Methodology, Writing – review & editing. OS: Visualization, Methodology, Writing – review & editing. LS: Resources, Supervision, Writing – review & editing. ME: Supervision, Writing – review & editing, Resources. SA-E: Supervision, Writing – review & editing. RA: Writing – review & editing, Supervision. AS: Supervision, Writing – review & editing. MH: Supervision, Writing – review & editing.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author RA declared that they was an editorial board member of Frontiers at the time of submission; this had no impact on the peer review process or the final decision.

Generative AI statement

The author(s) declared that Generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2026.1790597/full#supplementary-material

Image_1.jpg (5.2MB, jpg)
Image_2.jpg (2.5MB, jpg)
Image_3.jpg (1.4MB, jpg)

References

  1. Adasme M. F., Linnemann K. L., Bolz S. N., Kaiser F., Salentin S., Haupt V. J., et al. (2021). PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Res. 49, W530–W534. doi: 10.1093/nar/gkab294, [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Banerjee R., Humphries R. (2017). Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae. Virulence 8, 427–439. doi: 10.1080/21505594.2016.1185577, [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bassetti M., Nicolini L., Esposito S., Righi E., Viscoli C. (2009). Current status of newer carbapenems. Curr. Med. Chem. 16, 564–575. doi: 10.2174/092986709787458498, [DOI] [PubMed] [Google Scholar]
  4. Carattoli A., Zankari E., Garciá-Fernández A., Larsen M. V., Lund O., Villa L., et al. (2014). In silico detection and typing of plasmids using Plasmidfinder and plasmid multilocus sequence typing. Antimicrob. Agents Chemother. 58, 3895–3903. doi: 10.1128/AAC.02412-14, [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chen L., Yang J., Yu J., Yao Z., Sun L., Shen Y., et al. (2005). VFDB: a reference database for bacterial virulence factors. Nucleic Acids Res. 33, D325–D328. doi: 10.1093/nar/gki008, [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chen S., Zhou Y., Chen Y., Gu J. (2018). Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884–i890. doi: 10.1093/bioinformatics/bty560, [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Clinical and Laboratory Standards Institute (CLSI) (2023). M100 Performance Standards for Antimicrobial Susceptibility Testing. 33rd Edn Malvern, PA: Clinical and Laboratory Standards Institute. [Google Scholar]
  8. Dagher C., Salloum T., Alousi S., Arabaghian H., Araj G. F., Tokajian S. (2018). Molecular characterization of carbapenem resistant Escherichia coli recovered from a tertiary hospital in Lebanon. PLoS One 13, 1–13. doi: 10.1371/journal.pone.0203323, [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Docquier J. D., Calderone V., De Luca F., Benvenuti M., Giuliani F., Bellucci L., et al. (2009). Crystal structure of the OXA-48 β-lactamase reveals mechanistic diversity among class D carbapenemases. Chem. Biol. 16, 540–547. doi: 10.1016/j.chembiol.2009.04.010 [DOI] [PubMed] [Google Scholar]
  10. El-Gamal M. I., Brahim I., Hisham N., Aladdin R., Mohammed H., Bahaaeldin A. (2017). Recent updates of carbapenem antibiotics. Eur. J. Med. Chem. 131, 185–195. doi: 10.1016/j.ejmech.2017.03.022, [DOI] [PubMed] [Google Scholar]
  11. Elshamy A. A., Aboshanab K. M. (2020). A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options. Futur Sci OA 6:FSO438. doi: 10.2144/fsoa-2019-0098, [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Feldgarden M., Brover V., Gonzalez-Escalona N., Frye J. G., Haendiges J., Haft D. H., et al. (2021). AMRFinderPlus and the reference gene catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence. Sci. Rep. 11:12729: 12728. doi: 10.1038/s41598-021-91456-0, [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Findlay J., Duran J. B., Poirel L., Nordmann P. (2023). Emergence of OXA-484, an OXA-48–type beta-lactamase, in Switzerland. J. Glob. Antimicrob. Resist. 32, 131–133. doi: 10.1016/j.jgar.2023.01.010, [DOI] [PubMed] [Google Scholar]
  14. Findlay J., Hopkins K. L., Loy R., Doumith M., Meunier D., Hill R., et al. (2017). OXA-48-like carbapenemases in the UK: an analysis of isolates and cases from 2007 to 2014. J. Antimicrob. Chemother. 72, 1340–1349. doi: 10.1093/jac/dkx012, [DOI] [PubMed] [Google Scholar]
  15. Ge H., Qiao J., Xu H., Liu R., Zhao J., Chen R., et al. (2023). Emergence of OXA-484-producing Klebsiella variicola in China. Infect Drug Resist. 16, 1767–1775. doi: 10.2147/IDR.S404551, [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gonzalez C., Oueslati S., Rima M., Nermont R., Dortet L., Hopkins K. L., et al. (2024). Molecular, genetic, and biochemical characterization of OXA-484 carbapenemase, a difficult-to-detect R214G variant of OXA-181. Microorganisms 12:1391. doi: 10.3390/microorganisms12071391, [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hamzaoui Z., Ocampo-Sosa A., Fernandez Martinez M., Landolsi S., Ferjani S., Maamar E., et al. (2018). Role of association of OmpK35 and OmpK36 alteration and blaESBL and/or blaAmpC genes in conferring carbapenem resistance among non-carbapenemase-producing Klebsiella pneumoniae. Int. J. Antimicrob. Agents 52, 898–905. doi: 10.1016/j.ijantimicag.2018.03.020, [DOI] [PubMed] [Google Scholar]
  18. Hirvonen V. H. A., Spencer J., van der Kamp M. W. (2021). Antimicrobial resistance conferred by OXA-48 β-lactamases: towards a detailed mechanistic understanding. Antimicrob. Agents Chemother. 65, e00184–e00121. doi: 10.1128/AAC.00184-21, [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hooban B., Fitzhenry K., O’Connor L., Miliotis G., Joyce A., Chueiri A., et al. (2022). A longitudinal survey of antibiotic-resistant Enterobacterales in the Irish environment, 2019–2020. Sci. Total Environ. 828:154488. doi: 10.1016/j.scitotenv.2022.154488, [DOI] [PubMed] [Google Scholar]
  20. Hoyos-mallecot Y., Naas T., Bonnin R. A., Patino R., Glaser P., Fortineau N., et al. (2017). OXA-244-producing Escherichia coli isolates, a challenge for clinical microbiology laboratories. Antimicrob. Agents Chemother. 61:e00818-17. doi: 10.1128/AAC.00818-17, [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Huang J., Lv C., Li M., Rahman T., Chang Y. F., Guo X., et al. (2024). Carbapenem-resistant Escherichia coli exhibit diverse spatiotemporal epidemiological characteristics across the globe. Commun Biol. 7:51. doi: 10.1038/s42003-023-05745-7, [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Jalal D., Elzayat M. G., Diab A. A., El-Shqanqery H. E., Samir O., Bakry U., et al. (2021). Deciphering multidrug-resistant Acinetobacter baumannii from a pediatric cancer hospital in Egypt. mSphere 6. doi: 10.1128/mSphere.00725-21, [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Jalal D., Lotfi M., Ziad G. A., Mahfouz S., Madney Y., Bayoumi A., et al. (2025). Dual transmission dynamics of carbapenem resistance in pediatric oncology: plasmid-mediated and clonal spread of blaNDM-5 Enterobacterales. Infect. Dis. Ther. 15, 245–263. doi: 10.1007/s40121-025-01254-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Jankowski C. A. (2021). Influence of antimicrobial stewardship and molecular rapid diagnostic tests on antimicrobial prescribing for extended-spectrum Beta-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in bloodstream infection. Microbiol. Spectr. 9, 1–10. doi: 10.1128/Spectrum.00464-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Jolley K. A., Maiden M. C. J. (2010). BIGSdb: scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics 11. doi: 10.1186/1471-2105-11-595, [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Jomehzadeh N., Jahangirimehr F., Chegeni S. A. (2022). Virulence-associated genes analysis of carbapenemase-producing Escherichia coli isolates. PLoS One 17, 1–15. doi: 10.1371/journal.pone.0266787 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Jumper J., Evans R., Pritzel A., Green T., Figurnov M., Ronneberger O., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589. doi: 10.1038/s41586-021-03819-2, [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Larkin P. M. K., Realegeno S., Ward K. W., Garner O. B., Yang S. (2020). An unusual carbapenem resistant Escherichia coli carrying plasmid-mediated AmpC and mutated ompC in a patient with recurrent urinary tract infections. IDCases 20:e00781. doi: 10.1016/j.idcr.2020.e00781, [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Liu Z., Lei J., Zhang X., Yin J., Zhang Y., Lei K., et al. (2025). Evolution of ceftazidime-avibactam resistance driven by variation in blaKPC-2 to blaKPC-190 during treatment of ST11-K64 hypervirulent Klebsiella pneumoniae. Front. Cell. Infect. Microbiol. 15, 1–10. doi: 10.3389/fcimb.2025.1607127, [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Lotfi M., Jalal D., Sayed A. A. plsMD: a plasmid reconstruction tool from short-read assemblies. bioRxiv (2025). Available online at: 10.1101/2025.03.17.643493 [DOI]
  31. Luo Y., Luo R., Ding H., Ren X., Luo H., Zhang Y., et al. (2018). Characterization of carbapenem-resistant Escherichia coli isolates through the whole-genome sequencing analysis. Microb. Drug Resist. 24, 175–180. doi: 10.1089/mdr.2017.0079, [DOI] [PubMed] [Google Scholar]
  32. Madney Y., Mahfouz S., Bayoumi A., Hassanain O., Hassanain O., Sayed A. A., et al. (2025). Carbapenem-resistant Enterobacteriaceae (CRE) in children with cancer: the impact of rapid diagnostics and targeted colonization strategies on improving outcomes. Microorganisms 13, 1–11. doi: 10.3390/microorganisms13071627 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Masseron A., Poirel L., Falgenhauer L., Imirzalioglu C., Kessler J., Chakraborty T., et al. (2020). Ongoing dissemination of OXA-244 carbapenemase-producing Escherichia coli in Switzerland and their detection. Diagn. Microbiol. Infect. Dis. 97, 10–14. doi: 10.1016/j.diagmicrobio.2020.115059 [DOI] [PubMed] [Google Scholar]
  34. Oueslati S., Retailleau P., Marchini L., Berthault C., Dortet L., Bonnin R. A., et al. (2020). Role of arginine 214 in the substrate specificity of OXA-48. Antimicrob. Agents Chemother. 64. doi: 10.1128/AAC.02329-19, [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Papp-Wallace K. M., Endimiani A., Taracila M. A., Bonomo R. A. (2011). Carbapenems: past, present, and future. Antimicrob. Agents Chemother. 55, 4943–4960. doi: 10.1128/AAC.00296-11, [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Pedraza R., Kieffer N., Guzmán-Puche J., Artacho M. J., Pitart C., Hernández-García M., et al. (2022). Hidden dissemination of carbapenem-susceptible OXA-48-producing Proteus mirabilis. J. Antimicrob. Chemother. 77, 3009–3015. doi: 10.1093/jac/dkac267, [DOI] [PubMed] [Google Scholar]
  37. Perez F., El Chakhtoura N. G., Papp-Wallace K. M., Wilson B. M., Bonomo R. A. (2016). Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy? Expert. Opin. Pharmacother. 17, 761–781. doi: 10.1517/14656566.2016.1145658, [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Pitout J. D. D., Peirano G., Kock M. M., Strydom K. a. (2020). The global ascendency of OXA-48-type carbapenemases. Clin. Microbiol. Rev. 33:e00102-19. doi: 10.1128/CMR.00102-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Qin S., Cheng J., Wang P., Feng X., Liu H. M. (2018). Early emergence of OXA-181-producing Escherichia coli ST410 in China. J. Glob. Antimicrob. Resist. 15, 215–218. doi: 10.1016/j.jgar.2018.06.017, [DOI] [PubMed] [Google Scholar]
  40. Ramsamy Y., Mlisana K. P., Amoako D. G., Abia A. L. K., Ismail A., Allam M., et al. (2022). Mobile genetic elements-mediated Enterobacterales-associated carbapenemase antibiotic resistance genes propagation between the environment and humans: a one health south African study. Sci. Total Environ. 806:150641. doi: 10.1016/j.scitotenv.2021.150641, [DOI] [PubMed] [Google Scholar]
  41. Rima M., Emeraud C., Bonnin R. A., Gonzalez C., Dortet L., Iorga B. I., et al. (2021). Biochemical characterization of OXA-244, an emerging OXA-48 variant with reduced β-lactam hydrolytic activity. J. Antimicrob. Chemother. 76, 2024–2028. doi: 10.1093/jac/dkab142, [DOI] [PubMed] [Google Scholar]
  42. Robertson J., Nash J. H. E. (2018). MOB-suite: software tools for clustering, reconstruction and typing of plasmids from draft assemblies. Microb. Genom 4:e000206. doi: 10.1099/mgen.0.000206, [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Satlin M. J., Chen L., Gomez-Simmonds A., Marino J., Weston G., Bhowmick T., et al. (2022). Impact of a rapid molecular test for Klebsiella pneumoniae carbapenemase and ceftazidime-avibactam use on outcomes after bacteremia caused by carbapenem-resistant Enterobacterales. Clin. Infect. Dis. 75, 2066–2075. doi: 10.1093/cid/ciac354, [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Shien Lo T., Welch J. M., Alonto A. M., Vicaldo-Alonto E. A. R. (2012). A review of the carbapenems in clinical use and clinical trials. Front. Anti-Infect. Drug Discov. 1, 279–293. doi: 10.2174/978160805158811001010279 [DOI] [PubMed] [Google Scholar]
  45. Siguier P., Perochon J., Lestrade L., Mahillon J., Chandler M. (2006). Isfinder: the reference Centre for bacterial insertion sequences. Nucleic Acids Res. 34, D32–D36. doi: 10.1093/nar/gkj014, [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Slown S., Walas N., Amato H. K., Lloyd T., Varghese V., Bender M., et al. (2022). Clonal lineages and virulence factors of carbapenem resistant E. coli in Alameda County, California, 2017–2019. Antibiotics 11, 2017–2019. doi: 10.3390/antibiotics11121794 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Smith C. A., Stewart N. K., Toth M., Vakulenko S. B. (2019). Structural insights into the mechanism of carbapenemase activity of the OXA-48 β-lactamase. Antimicrob. Agents Chemother. 63, 1–14. doi: 10.1128/aac.01202-19, [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Stojanoski V., Hu L., Sankaran B., Wang F., Tao P., Prasad B. V. V., et al. (2021). Mechanistic basis of OXA-48-like β-lactamases’ hydrolysis of carbapenems. ACS Infect. Dis. 7, 445–460. doi: 10.1021/acsinfecdis.0c00798, [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Tamma P. D., Aitken S. L., Bonomo R. A., Mathers A. J., Van Duin D., Clancy C. J. (2022). Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin. Infect. Dis. 75, 187–212. doi: 10.1093/cid/ciac268, [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Tilahun M., Kassa Y., Gedefie A., Ashagire M. (2021). Emerging carbapenem-resistant Enterobacteriaceae infection, its epidemiology and novel treatment options: a review. Infect. Drug Resist. 14, 4363–4374. doi: 10.2147/IDR.S337611, [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Wick R. R., Judd L. M., Gorrie C. L., Holt K. E. (2017). Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput. Biol. 13, 1–22. doi: 10.1371/journal.pcbi.1005595 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Wong J. L. C., Romano M., Kerry L. E., Kwong H. S., Low W. W., Brett S. J., et al. (2019). OmpK36-mediated carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo. Nat. Commun. 10, 1–10. doi: 10.1038/s41467-019-11756-y, [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Yu Z., Zhang Z., Shi L., Hua S., Luan T., Lin Q., et al. (2022). In silico characterization of IncX3 plasmids carrying blaOXA-181 in Enterobacterales. Front. Cell. Infect. Microbiol. 12, 1–9. doi: 10.3389/fcimb.2022.988236, [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Ziad G. A., Jalal D., Hashem M., Sayed A. A., Mahfouz S., Bayoumi A., et al. (2025). Rapid identification of carbapenemase genes directly from blood culture samples. Diagnostics 15:2480. doi: 10.3390/diagnostics15192480, [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Image_1.jpg (5.2MB, jpg)
Image_2.jpg (2.5MB, jpg)
Image_3.jpg (1.4MB, jpg)

Data Availability Statement

All data generated and analyzed during this study are included in this article and published online on NCBI with the SRA accession number PRJNA1209707.

Articles from Frontiers in Microbiology are provided here courtesy of Frontiers Media SA

RESOURCES